HBM Healthcare Investments

SW: HBMN

€2133.2m market cap

€306.5 last close

HBM Healthcare Investments (formerly HBM BioVentures, renamed in 2012) is a Swiss investment company that aims to generate long-term capital gains by investment in private and public companies in the human medicine, biotech, medtech and diagnostic sectors, and related areas. It invests worldwide, predominantly in later-stage private companies (either directly or through funds) and publicly listed holdings, many of which began as private equity investments.

Investment summary

HBM Healthcare Investments’ (HBMN’s) portfolio is still in line for a positive FY20 (NAV TR +13.2% at 24 March 2020 compared with the 31 March FY19 year-end), with the share price largely flat (+1.3%) over the 51 weeks despite the recent global stock market sell-off. Its managers attribute the relative strength to a combination of strong IPO activity from the private portfolio, taking profits in some listed holdings as markets peaked in February, and hedging (through short index positions) in the public portfolio, which generated proceeds of c CHF45m as indices declined. The team is remaining prudent with regard to new private investments (only one has been made so far in 2020), in expectation of more attractive valuations later in the year, but is willing to deploy some of its large cash pile in response to value opportunities in listed markets. Meanwhile, it remains on track to declare a 3–5% distribution for FY20.

Register to receive research on HBM Healthcare Investments as it is published
Share price graph
Price performance
%
1m
3m
12m
Actual 4.3 13.5 32.5
Relative* 0.2 5.2 31.3
52-week high/low €309.0/€149.9
*% relative to local index
Key management
Andreas Wicki CEO
Erwin Troxler CFO